Core Viewpoint - Tongce Medical (600763) reported a slight decline in stock price, with a closing price of 41.9 yuan on November 26, 2025, down 0.12% from the previous day [1] Financial Performance - For the first three quarters of 2025, Tongce Medical achieved a main business revenue of 2.29 billion yuan, a year-on-year increase of 2.56% [3] - The net profit attributable to shareholders was 514 million yuan, up 3.16% year-on-year [3] - The third quarter alone saw a main business revenue of 842 million yuan, reflecting a 2.34% increase year-on-year [3] - The company reported a gross profit margin of 41.69% and a net profit margin of 26.91% [3] Market Position - Tongce Medical's total market capitalization is 18.741 billion yuan, ranking 8th in the medical services industry [3] - The company has a price-to-earnings ratio (P/E) of 27.37, significantly lower than the industry average of 366.11, ranking 3rd in the industry [3] - The return on equity (ROE) stands at 11.8%, placing it 5th in the industry [3] Fund Flow Analysis - On November 26, 2025, the net inflow of main funds was 9.8015 million yuan, accounting for 5.38% of the total transaction amount [1][2] - Retail investors experienced a net outflow of 11.9863 million yuan, representing 6.58% of the total transaction amount [1][2] - Over the past five days, the stock has seen fluctuations in fund flows, with notable net outflows from retail investors on several days [2] Analyst Ratings - In the last 90 days, 10 institutions have rated the stock, with 7 buy ratings and 3 hold ratings [4] - The average target price set by analysts over the past 90 days is 51.78 yuan [4]

Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

证券代码：600763 证券简称：通策医疗 公告编号：2025-032 通策医疗股份有限公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东会类型和届次 2025年第一次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 10 日 15 点 00 分 召开地点：杭州市西湖区西溪路双口井巷 1 号通策医疗大厦 7 楼报告厅 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 12 月 10 日 | 序号 | 议案名称 | 投票股东类型 | | --- | --- | --- | | | | 股股东 A | | 非累积投票议案 | | | | 1.00 | 关于修订《公司章程》及其他制度的议案 | √ | | 1.01 ...

证券之星消息，截至2025年11月20日收盘，通策医疗(600763)报收于43.22元，下跌1.28%，换手率 0.89%，成交量3.99万手，成交额1.74亿元。 11月20日的资金流向数据方面，主力资金净流出1974.79万元，占总成交额11.38%，游资资金净流出 48.71万元，占总成交额0.28%，散户资金净流入2023.5万元，占总成交额11.66%。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-20 | 43.22 | -1.28% | -1974.79万 | -11.38% | -48. ...

Group 1 - The core viewpoint of the news is that Tongce Medical (600763) has shown stable financial performance with a slight increase in stock price and mixed capital flow data as of November 18, 2025 [1][2][3] Group 2 - As of November 18, 2025, Tongce Medical's stock closed at 44.14 yuan, with a slight increase of 0.05% and a trading volume of 58,200 hands, resulting in a transaction amount of 259 million yuan [1] - The net inflow of main funds was 7.49 million yuan, accounting for 2.9% of the total transaction amount, while retail investors experienced a net outflow of 6.22 million yuan, representing 2.41% of the total transaction amount [1] - In the last five days, the stock has seen fluctuations in capital flow, with significant net outflows from retail investors on several days [1] Group 3 - Key financial metrics for Tongce Medical include a total market value of 19.743 billion yuan, net assets of 4.703 billion yuan, and a net profit of 514 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 2.56% in revenue and 3.16% in net profit [2] - The company's gross profit margin stands at 41.69%, with a net profit margin of 26.91%, indicating strong profitability compared to industry averages [2] - The company ranks well within the industry, with a price-to-earnings ratio of 28.84, placing it third among its peers [2] Group 4 - Over the past 90 days, 11 institutions have rated the stock, with 8 buy ratings and 3 hold ratings, indicating positive sentiment among analysts [3] - The average target price set by institutions for the stock is 51.78 yuan, suggesting potential upside from the current trading price [3]

Core Points - Tongce Medical (600763) closed at 44.68 yuan on November 14, 2025, up 5.4% from 42.39 yuan the previous week [1] - The company's market capitalization is currently 19.985 billion yuan, ranking 9th out of 50 in the medical services sector and 974th out of 5165 in the A-share market [1] Company Announcements - The controlling shareholder, Baoqun Industrial, holds 33.89% of the company's shares and has pledged 21.33 million shares, which accounts for 14.07% of its holdings and 4.77% of the total share capital [2][3] - Baoqun Industrial has also released a pledge of 19.32 million shares, representing 12.74% of its holdings and 4.32% of the total share capital [2][3] - After these changes, Baoqun Industrial has a total of 101.036672 million pledged shares, which is 66.65% of its holdings and 22.59% of the total share capital [2][3] - The associated party, Lv Jianming, holds 0.47% of the shares with no pledges, indicating that the pledge risk is controllable [2][3]

Core Viewpoint - Tongce Medical (600763) experienced a slight decline in stock price, closing at 44.68 yuan on November 14, 2025, with a trading volume of 9.94 million shares and a turnover of 449 million yuan [1] Group 1: Stock Performance and Trading Data - On November 14, 2025, the net outflow of main funds was 11.47 million yuan, accounting for 2.56% of the total turnover, while retail funds saw a net inflow of 25.42 million yuan, representing 5.67% of the total turnover [1] - The stock's performance over the past five days shows fluctuations, with a notable drop on November 13, where the stock price was 44.75 yuan, reflecting a 0.36% increase, but with a significant net outflow of main funds at 38.44 million yuan, which was 12.79% of the total [2] Group 2: Financial Metrics and Industry Comparison - As of the latest report, Tongce Medical's total market value is 19.985 billion yuan, with a net asset of 4.703 billion yuan and a net profit of 514 million yuan, ranking 8th, 12th, and 6th respectively in the medical services industry [3] - The company reported a year-on-year revenue increase of 2.56% for the first three quarters of 2025, totaling 2.29 billion yuan, with a net profit of 514 million yuan, reflecting a 3.16% increase [3] - The gross profit margin stands at 41.69%, significantly higher than the industry average of 35.56%, and the net profit margin is 26.91%, compared to the industry average of 4.43% [3] Group 3: Analyst Ratings and Target Price - In the last 90 days, 11 institutions have rated the stock, with 8 buy ratings and 3 hold ratings, indicating a positive outlook [4] - The average target price set by analysts over the past 90 days is 51.78 yuan, suggesting potential upside from the current trading price [4]

Core Viewpoint - Tongce Medical (600763) shows a slight increase in stock price and mixed capital flow, indicating potential investor interest and market dynamics [1][2]. Group 1: Stock Performance - As of November 13, 2025, Tongce Medical's stock closed at 44.75 yuan, up 0.36% with a turnover rate of 1.51% and a trading volume of 67,500 hands, resulting in a transaction amount of 301 million yuan [1]. - Over the past five days, the stock has experienced fluctuations in capital flow, with a net outflow of 38.44 million yuan from main funds on November 13, accounting for 12.79% of the total transaction amount [2]. Group 2: Financial Metrics - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [3]. - The company's third-quarter performance included a single-quarter main revenue of 842 million yuan, reflecting a 2.34% year-on-year increase, and a net profit of 192 million yuan, up 2.31% year-on-year [3]. Group 3: Industry Comparison - Tongce Medical's total market value stands at 20.016 billion yuan, slightly above the industry average of 19.945 billion yuan, ranking 8th in the industry [3]. - The company has a net profit margin of 26.91%, significantly higher than the industry average of 4.43%, ranking 3rd in the industry [3]. Group 4: Analyst Ratings - In the last 90 days, 11 institutions have rated Tongce Medical, with 8 buy ratings and 3 hold ratings, indicating a generally positive outlook [4]. - The average target price set by institutions over the past 90 days is 51.78 yuan, suggesting potential upside from the current trading price [4].

Summary of Key Points Core Viewpoint - Tongce Medical (600763) experienced a slight decline in stock price, closing at 44.59 yuan on November 12, 2025, with a trading volume of 72,400 shares and a total transaction value of 324 million yuan [1]. Trading Information - On November 12, the net outflow of main funds was 12.72 million yuan, accounting for 3.93% of the total transaction value [2]. - Retail investors saw a net inflow of 20.33 million yuan, representing 6.28% of the total transaction value [1]. Company Announcements - The controlling shareholder, Baoqun Industrial, pledged 21.33 million shares, which is 14.07% of its holdings and 4.77% of the total share capital [1]. - Baoqun Industrial also released a pledge of 19.32 million shares, which is 12.74% of its holdings and 4.32% of the total share capital [1]. - After these transactions, Baoqun Industrial has a total of 101.04 million shares pledged, which is 66.65% of its holdings and 22.59% of the total share capital [1].

Group 1 - The core point of the article highlights that Tongce Medical (SH 600763) announced that Baohun Industrial has pledged approximately 101 million shares, accounting for 66.65% of Baohun's holdings and 22.59% of the total shares of the company [1] - Baohun Industrial's consistent action person, Mr. Lv Jianming, holds about 2.09 million shares, which is 0.47% of the total share capital, and has no pledged shares [1] - As of the report, Tongce Medical's market capitalization is 20 billion yuan [1] Group 2 - For the first half of 2025, Tongce Medical's revenue composition is as follows: medical services account for 92.84%, product sales for 4.06%, construction engineering for 2.72%, and others for 0.38% [1]